May 1, 2022 Issue of JAMA Oncology

May 2022, Vol 8, No. 5, Pages 669-788

Original Investigation

Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer

Michael S. Leapman, MD; Michaela Dinan, PhD; Saamir Pasha, MPH; et al.

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):687-696. doi:10.1001/jamaoncol.2021.8116

This cohort study uses data from the Surveillance, Epidemiology, and End Results database to identify clinical, sociodemographic, and structural processes underlying racial disparity in the use of prostate magnetic resonance imaging among men with a new diagnosis of prostate cancer.

Invited Commentary
Racist Factors Underlying Prostate Cancer Disparities
Michael Poulson, MD, MPH

JAMA Oncol

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial

Xavier Pivot, MD, PhD; M. A. Georgievich, MD; Volodymyr Shamrai, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2022;8(5):698-705. doi:10.1001/jamaoncol.2021.8171

This randomized clinical trial compare the efficacy of HD201 with referent trastuzumab for treating patients with ERBB2-positive breast cancer.

Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial

Wang-Zhong Li, MD; Xing Lv, MD; Dan Hu, MS; et al.

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):706-714. doi:10.1001/jamaoncol.2022.0122

This phase 3 randomized clinical trial examines whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine improves survival vs cisplatin and fluorouracil prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma.

Invited Commentary
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma鈥擨s This the New Standard of Care?
Maurice Willis, MD

JAMA Oncol

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Kenneth L. Kehl, MD, MPH; David Zahrieh, PhD; Ping Yang, MD, PhD; et al.

Abstract Full Text

free access has audio

JAMA Oncol. 2022;8(5):717-728. doi:10.1001/jamaoncol.2022.0039

This cohort study examines patterns of guideline-concordant treatment among patients enrolled in a US-wide screening protocol for adjuvant treatment trials for resected non-small cell lung cancer.

Podcast: Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer

Invited Commentary
Translating Clinical Trial Evidence to Routine Practice鈥擧ow Do We Overcome the Barriers?
Monica Tang, MBBS, MMed; Chee Khoon Lee, MBBS, MMedSci, MBiostat, PhD

JAMA Oncol

Risk of Colorectal Cancer Associated With Lifetime Excess Weight

Xiangwei Li, MSc; Lina Jansen, PhD; Jenny Chang-Claude, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):730-737. doi:10.1001/jamaoncol.2022.0064

This case-control study examines the use of a measure estimating the association between cumulative lifetime exposure to excess weight and the risk for colorectal cancer.

Invited Commentary
Exposure Histories and Cancer Risk鈥擶hat Can We Learn?
Patrick T. Bradshaw, PhD

JAMA Oncol

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial

Robin L. Jones, MD; Vinod Ravi, MD; Andrew S. Brohl, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2022;8(5):740-747. doi:10.1001/jamaoncol.2021.3547

This randomized clinical trial investigates whether carotuximab plus pazopanib improves progression-free survival vs pazopanib alone in adult patients with advanced angiosarcoma.

Association of Patient-Reported Outcomes With Subsequent Nonfatal Self-injury After a New Cancer Diagnosis

Julie Hallet, MD, MSc; Rinku Sutradhar, PhD; Elie Isenberg-Grzeda, MDCM; et al.

Abstract Full Text

free access online only

JAMA Oncol. 2022;8(5):e220203. doi:10.1001/jamaoncol.2022.0203

This case-control study examines the associations between patient-reported outcome measures and subsequent nonfatal self-injury in patients with cancer.

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Michel Obeid, MD, PhD; Madeleine Suffiotti, PhD; Celine Pellaton, PhD; et al.

Abstract Full Text

open access online only has active quiz

JAMA Oncol. 2022;8(5):e220446. doi:10.1001/jamaoncol.2022.0446

This comparative effectiveness study of immunocompromised patients and healthy controls in Switzerland examines differences in the magnitude and durability of neutralizing antibody responses against the original SARS-CoV-2 and several variants of concern according to the mRNA-1273 and BNT162b2 vaccines.

Brief Report

Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida

Anna R. Giuliano, PhD; Jeffrey E. Lancet, MD; Shari Pilon-Thomas, PhD; et al.

Abstract Full Text

open access has active quiz

JAMA Oncol. 2022;8(5):748-754. doi:10.1001/jamaoncol.2022.0001

This cohort study investigates the immune response of patients with cancer to the first and second doses of the COVID-19 mRNA-1273 vaccination.

Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018

Michael L. Chen, BA; Isabella Joy de Vere Hunt, MD; Esther M. John, PhD, MSPH; et al.

Abstract Full Text

open access

JAMA Oncol. 2022;8(5):755-759. doi:10.1001/jamaoncol.2022.0134

This population-based cohort study examines patterns in tumor thickness鈥搒pecific incidence in patients with cutaneous melanoma.

Research Letter

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Joanna C. Zurko, MD; Bryon D. Johnson, PhD; Emilie Aschenbrenner, PharmD; et al.

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):773-775. doi:10.1001/jamaoncol.2022.0070

This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.

Self-reported Transportation Barriers to Health Care Among US Cancer Survivors

Changchuan Jiang, MD, MPH; K. Robin Yabroff, PhD, MBA; Lei Deng, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):775-778. doi:10.1001/jamaoncol.2022.0143

This cross-sectional study uses data from the 2014-2018 National Health Interview Survey to examine various characteristics of US cancer survivors who experience delays in care due to transportation barriers.

Association of Changes in Medicaid Dental Benefits With Localized Diagnosis of Oral Cavity Cancer

Lulia A. Kana, MD, MS; Evan M. Graboyes, MD, MPH; Daniel Quan, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):778-780. doi:10.1001/jamaoncol.2022.0149

This cohort study uses data from the Surveillance, Epidemiology, and End Results database to examine the association between changes in Medicaid dental insurance coverage in California between 2009 and 2014 and rates of localized oral cavity cancer diagnoses.

Review

Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review

John H. Strickler, MD; Takayuki Yoshino, MD, PhD; Rondell P. Graham, MBBS; et al.

Abstract Full Text

has active quiz

JAMA Oncol. 2022;8(5):760-769. doi:10.1001/jamaoncol.2021.8196

This review explores the characteristics of ERBB2-positive metastatic colorectal cancer and the potential of treatment with anti-ERBB2 agents.

JAMA Oncology Clinical Challenge

An Intramedullary Enigma

Nayan Lamba, MD; Danielle S. Bitterman, MD

Abstract Full Text

has active quiz

JAMA Oncol. 2022;8(5):770-771. doi:10.1001/jamaoncol.2022.0462

A woman in her 60s was diagnosed with high-grade leiomyosarcoma of the uterus, which had been treated with hysterectomy and bilateral salpingo-oophorectomy, and subsequently had relapsed in the liver and spine. What is your diagnosis?

Viewpoint

Oncological Applications of Deep Learning Generative Adversarial Networks

Harrison Phillips; Shelly Soffer, MD; Eyal Klang, MD

Abstract Full Text

JAMA Oncol. 2022;8(5):677-678. doi:10.1001/jamaoncol.2021.8202

This Viewpoint assesses the use of generative adversarial networks to overcome current challenges and further revolutionize the use of deep learning in oncology.

Biased Evaluation in Cancer Drug Trials鈥擧ow Use of Progression-Free Survival as the Primary End Point Can Mislead

Ian F. Tannock, MD, PhD; Gregory R. Pond, PhD; Christopher M. Booth, MD

Abstract Full Text

JAMA Oncol. 2022;8(5):679-680. doi:10.1001/jamaoncol.2021.8206

This Viewpoint discusses whether the use of progression-free survival as the primary end point in cancer drug trials can result in misleading interpretations of improved overall survival and quality of life.

Palliative Care Is the Umbrella, Not the Rain鈥擜 Metaphor to Guide Conversations in Advanced Cancer

Camilla Zimmermann, MD, PhD; Jean Mathews, MD

Abstract Full Text

JAMA Oncol. 2022;8(5):681-682. doi:10.1001/jamaoncol.2021.8210

This Viewpoint provides a metaphor for physicians to use as a communication tool to explain the benefits of early palliative care to patients with advanced cancer.

Editorial

JAMA Oncology鈥擳he Year in Review, 2021

Mary L. (Nora) Disis, MD

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):685-686. doi:10.1001/jamaoncol.2022.0262

Invited Commentary

Racist Factors Underlying Prostate Cancer Disparities

Michael Poulson, MD, MPH

Abstract Full Text

JAMA Oncol. 2022;8(5):696-697. doi:10.1001/jamaoncol.2021.7271

Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma鈥擨s This the New Standard of Care?

Maurice Willis, MD

Abstract Full Text

JAMA Oncol. 2022;8(5):715-716. doi:10.1001/jamaoncol.2022.0082

Translating Clinical Trial Evidence to Routine Practice鈥擧ow Do We Overcome the Barriers?

Monica Tang, MBBS, MMed; Chee Khoon Lee, MBBS, MMedSci, MBiostat, PhD

Abstract Full Text

JAMA Oncol. 2022;8(5):728-729. doi:10.1001/jamaoncol.2022.0038

Exposure Histories and Cancer Risk鈥擶hat Can We Learn?

Patrick T. Bradshaw, PhD

Abstract Full Text

JAMA Oncol. 2022;8(5):738-739. doi:10.1001/jamaoncol.2022.0061

JAMA Oncology Patient Page

Financial Toxicity of Cancer Treatment

S. M. Qasim Hussaini, MD, MS; Arjun Gupta, MD; Stacie B. Dusetzina, PhD

Abstract Full Text

free access

JAMA Oncol. 2022;8(5):788. doi:10.1001/jamaoncol.2021.7987

This JAMA Oncology Patient Page explains what financial toxicity is and offers treatment approaches.

Cancer Care Chronicles

A Radiation Oncologist鈥檚 Experience With Medical Aid in Dying

Santosh V. Yajnik, MD

Abstract Full Text

JAMA Oncol. 2022;8(5):683-684. doi:10.1001/jamaoncol.2022.0076

This essay discusses medical aid in dying (MAID) and encourages physicians to inquire about medical societies鈥� stances on MAID and to consider a position of engaged neutrality.

Poetry and Oncology